brain/
← all entities
entityWSTstock-market

West Pharmaceutical Services (NYSE: WST)

Notes

West Pharmaceutical Services (NYSE: WST)

One-line summary: Q2 FY2026 sales $872.3M (+13.8% reported / +12.7% organic); FY26 raised to $3.345–$3.380B / $8.85–$9.05 adj EPS. GLP-1 mix is deck-only: 10% elastomer + 8% West Vantage = 18% of Q2 net sales — not all-elastomer tightness.

What it is

Large-cap US manufacturer of elastomeric (rubber) stoppers, seals, and plungers for injectable drug vials and prefilled syringes. Every injectable vial and prefilled syringe — including for GLP-1 drugs — needs a West elastomeric component. These are high-precision consumables with a one-per-dose relationship to volume. West's High-Value Products (HVP) line specifically serves GLP-1 drugs.

Why it matters to stock-market

WST is the elastomeric layer of the GLP-1 supply chain. Every additional GLP-1 injectable dose is a direct dollar of WST revenue — a consumable-based, dose-volume-driven model with minimal ability to substitute. Unlike fill-finish CDMOs, WST is less exposed to in-house captive manufacturing risk (stoppers are commodity-like in specification, high in precision, and substitution is complex).

Valuation (August 27, 2026)

Last: $346.09 at the Thu 27 Aug 2026 4:00 PM EDT close. From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware.

Gage's judgment (as of 2026-08-27)

Gage, 27 Aug 2026, via Leo. ~15% up / ~20% down over 12–18 months. Watch, not buy. Gage's judgment, not grain / not issuer fact. Last-price as-of stays the vault last: $346.09 (Thu 27 Aug 2026 4:00 PM EDT). 18% mix stays deck-only. Orals live. Pricing-power gap still open. Not a buy/sell/size. Not a paper sleeve. No source URL — do not invent one.

Key facts

  • Q2 FY2026 print (8-K 23 Jul 2026 + IR): sales $872.3M, +13.8% reported / +12.7% organic. Diluted EPS $2.15; adj $2.37. From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware.
  • FY26 guidance raised: $3.345–$3.380B sales / $8.85–$9.05 adj EPS. Prior on the same page: $3.295–$3.350B / $8.40–$8.75. From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware.
  • Segment organics (Q2): HVP Components $424.1M +18.4%; HVP Delivery Devices $131.2M +29.2%; West Vantage $149.7M +0.8%. From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware.
  • GLP-1 mix is DECK-ONLY: 10% elastomer + 8% West Vantage = 18% of Q2 net sales. Do not treat 18% as all-elastomer tightness. IR names GLP-1 elastomers qualitatively only (Green: HVP Components on biologics, Annex 1, ongoing growth in GLP-1 elastomers). From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware.
  • Official WST transcript was not retrieved. West-hosted oral-cannibalization quotes stay out. From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware.
  • Orals are a live derailer, not a printed mix collapse. Foundayo FDA-approved 1 April 2026, shipping 6 April. Wegovy pill 3M Rx since 5 Jan 2026; >80% of new Rx new-to-GLP-1 (expanding, not replacing). Class-level oral share >30% is not established — do not treat brand tape as class share. WST mix is up, not down. Injectable unit volumes still undisclosed. From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware.
  • 503B still a proposal (closing, not reopening). 91 FR 23431 (1 May 2026) proposes not to list semaglutide / tirzepatide / liraglutide; original comment deadline June 30; extended to July 30, 2026 (FR-2026-12937, fetched). No final rule fetched. From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware.
  • June honest gap stays open: pricing power vs normalized capacity still inferred. Q2 mix-up is not a unit-volume or rent-capture print. Same source.
  • GLP-1 as % of net sales (FY2025 prior): 17% of FY2025 net sales; grew ~50% YoY. GLP-1 elastomers were 10% of Q4 2025 revenues; GLP-1 contract manufacturing was 7% of Q4 2025. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries.
  • Q1 2026 prior: Revenues grew 15% organically, led by HVP components with double-digit growth in GLP-1 and non-GLP-1 products. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries.
  • FY2026 guidance (Q1 prior, superseded by Q2 raise): $3.295B–$3.350B revenues; organic growth 5-7%; HVP components growing high-single to low-double-digit organically. GLP-1 alone ~+1pp to organic growth (conservative assumption per management). From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries.
  • Oral GLP-1 as volume expander (Q1-era prior): Management explicitly stated "eight of ten patients using oral GLP-1s are new to the market" — oral pills expand total user population, not cannibalizing injectables, protecting WST's elastomer volume. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries. Not restated on the Q2 IR/8-K/deck fetched this pass.
  • GLP-1 ~18% of net sales (Q1 prior): ~10% elastomer + ~8% West Vantage; FY2026 guidance then $3.295–3.350B / $8.40–8.75 adj-EPS. From 2026-06-15-autoresearch-glp1-medicare-bridge-503b-ban-wst-injectable-demand. Q2 deck reprints the 10+8 split; the dollar/EPS guide is the raised range above.
  • Oral-substitution counter-evidence (Q1'26 prior): HVP Delivery Devices net sales +29.0% YoY, driven by self-injection-device platforms for obesity/diabetes; West announced a new ~165,000-sq-ft injectable-component facility (late March 2026). Delivers >41B components/devices/yr across 26 facilities. From 2026-06-15-autoresearch-glp1-medicare-bridge-503b-ban-wst-injectable-demand. Q2 HVP Delivery Devices +29.2% organic is the same-direction print; do not flatten it into an unfetched oral-cannibalization quote.

Strengths

  • NYSE large-cap, liquid; GLP-1 mix now reprinted on the Q2 deck (18% = 10% elastomer + 8% West Vantage)
  • Consumable model: every dose uses one elastomeric component; demand is volume-linear
  • HVP Delivery Devices still +29% organic in Q2 — realized injectable-device growth continues
  • FY26 sales and adj-EPS guide raised on the Q2 IR/8-K

Risks

  • 18% is not all elastomer; West Vantage (8% of the mix) printed only +0.8% organic
  • Official Q2 transcript not retrieved — West-hosted oral-vs-injectable color is open; brand-level oral tape is filed, class share is not
  • Oral derailer is live (Foundayo shipping; Wegovy pill expanding). Class-level oral share >30% not established. Mix is up; units undisclosed.
  • Management's earlier "~+1pp organic growth" GLP-1 contribution was conservative — volume miss if GLP-1 script growth decelerates remains a risk
  • Margin dilution if GLP-1 contract manufacturing grows faster than HVP components (higher margin)

Open questions

  • Official WST Q2 transcript (West-hosted or SEC): Green orals expanding vs cannibalizing; +4 pts price; Dublin ramp (31 Mar IR) — unfetched.
  • Class-level oral share >30% — not established.
  • June honest gap: pricing power vs normalized capacity — still inferred.
  • Gage range is on this page as Gage's judgment (Gage, 27 Aug 2026, via Leo), not grain.

Sources

Related

Referenced by
Mechanisms
GLP-1 demand surge → four-layer manufacturing bottleneck → Bachem / Stevanato / West Pharma / Ypsomed
Entities
Eli LillyStevanato Group (NYSE: STVN)Ypsomed AG (SWX: YPSN)
Sources
Eli Lilly checkpoints: Q3, Foundayo, BLA, Bridge